+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 55 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.

Age: 5Years - 60YearsAll GendersPhase 3
419 locations
E

Actively Recruiting

Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.

Age: 18Years +All GendersPhase 3
433 locations
A

Actively Recruiting

Researchers are evaluating an adaptive clinical decision support CDS system called EMBED to help emergency department ED physicians follow standard care in administering buprenorphine to patients with opioid use disorder. This study is part of a larger ongoing research project using a Multiphase Optimization Strategy MOST to improve the EMBED systems usability and effectiveness in real-world settings. The goal is to increase the number of physicians initiating buprenorphine treatment in the ED. The study involves comparing two versions of the EMBED CDS a refined version based on earlier results, and a refined version plus an alert to providers when a nurse completes the Clinical Opioid Withdrawal Scale COWS assessment. Participants are randomized to receive one of these versions, and multiple rounds of testing are planned to iteratively improve the system. The EMBED CDS integrates into the electronic health record workflow to assist with diagnosing opioid use disorder, assessing withdrawal severity, motivating patients with brief interviews, and automating documentation and prescribing. Participants are emergency department patients aged 18 or older with moderate to severe opioid use disorder. The study measures include the proportion of encounters where buprenorphine is initiated in the ED, engagement with the CDS, how buprenorphine orders are placed, time spent using the EMBED system, and task completion rates. The trial runs from August 2026 to February 2027, with data collection up to 3 months per trial round. Safety and follow-up are managed through the studys electronic system integration.

Age: 18Years +All GendersPhase Not Applicable
3 locations
O

Actively Recruiting

Researchers are evaluating the EMBED clinical decision support system to improve emergency department ED physicians adherence to standard care for administering buprenorphine to patients with opioid use disorder OUD. This study uses a Multiphase Optimization Strategy MOST framework, including preparation, optimization, and confirmatory phases, to refine and optimize EMBED for better usability and implementation. The goal is to enhance treatment initiation rates during emergency care for individuals with OUD. The optimization phase has two stages Stage 1 involves a 2x2x2 factorial trial testing sustainable implementation strategies such as nurse prompts for withdrawal assessment, targeted clinician prompts to use the CDS, and patient-facing materials to promote equity and motivate readiness for treatment. Stage 2 focuses on improving CDS usability through serial randomized testing to minimize user errors, workflow disruption, and abandonment by refining the interface and workflow. In the evaluation phase, a randomized trial compares the effectiveness of the optimized package with the original EMBED system on rates of buprenorphine initiation in the ED. Participants engage with the clinical decision support integrated into the electronic health record workflow, which assists in diagnosing OUD, assessing withdrawal severity, motivating patients through brief negotiation interviews, and automating documentation, order entry, prescribing, and referral for ongoing care. Researchers measure outcomes including the proportion of ED encounters with buprenorphine initiation and CDS engagement. The study spans multiple phases with continuous assessment to refine and confirm improvements in treatment initiation over time.

Age: 18Years +All GendersPhase Not Applicable
3 locations
N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
S

Actively Recruiting

Researchers are evaluating whether adding nivolumab to the usual treatment of paclitaxel and ramucirumab improves outcomes for patients with advanced gastric or esophageal adenocarcinoma that has spread locally or to distant sites. This phase IIIII trial aims to compare progression-free survival and overall survival between the combination including nivolumab and the standard regimen without it. The study also assesses response rates, disease control, safety, and quality of life measures to understand the impact of this treatment approach. Participants are randomly assigned to one of two treatment groups. One group receives nivolumab intravenously on day 1, ramucirumab intravenously on days 1 and 15, and paclitaxel intravenously on days 1, 8, and 15 of each 28-day cycle. The other group receives ramucirumab and paclitaxel on the same schedule without nivolumab. Treatment cycles continue every 28 days unless the disease progresses or unacceptable side effects occur. Imaging scans including CT and MRI are performed regularly throughout the study, and optional blood samples may be collected. During the trial, participants undergo assessments including imaging scans and quality of life questionnaires. Follow-up visits occur at 30, 60, and 90 days after treatment ends, then every six months for up to three years. Researchers measure outcomes such as progression-free survival, overall survival, response rates, disease control, and adverse events. Patient-reported symptoms and health-related quality of life are also evaluated to monitor treatment effects and tolerability over time.

Age: 18Years +All GendersPhase 2Phase 3
378 locations
R

Actively Recruiting

Researchers are evaluating the impact of adding locoregional treatments such as surgery and radiation, along with metastasis-targeted stereotactic body radiation therapy SBRT, to the usual HER2-targeted systemic therapy for patients with HER2-positive stage IV breast cancer that has spread to other parts of the body or to a limited number of sites oligometastatic. The study compares this multimodal approach to standard systemic therapy alone, aiming to assess overall survival and disease progression outcomes. This phase III trial includes patients whose cancers respond partially or completely to initial systemic therapy and also observes those with stable or progressing disease. Participants first receive standard HER2-targeted systemic treatments for 12 to 24 weeks, possibly including immunotherapy and chemotherapy drugs. Those with a positive response are randomized into two groups one group undergoes surgery and locoregional radiation therapy, followed by SBRT targeting metastatic lesions, then resumes systemic therapy the other group continues systemic therapy alone. Patients without a response continue systemic therapy in an observational cohort. Procedures such as breast conserving therapy or total mastectomy, radiation therapy with or without boost doses, and SBRT are delivered within specific timeframes post initial treatment. Throughout the study, participants undergo various imaging tests including echocardiography ECHO, MRI, mammography, ultrasound, CT, and PETCT scans, with optional biopsies and blood sample collections. Researchers monitor overall survival and progression-free survival for up to 10 years after treatment, with follow-up visits at regular intervals. The study also tracks treatment adherence, disease status, and side effects, aiming to understand the long-term effects of adding locoregional therapies to systemic treatment in this patient group.

Age: 18Years +All GendersPhase 3
59 locations
R

Actively Recruiting

Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2Phase 3
413 locations
R

Actively Recruiting

Researchers are evaluating treatments for people diagnosed with Stage I HER2-positive invasive breast cancer. This study compares two combinations of HER2-targeted therapies given after surgery to see how well they work and their side effects. The study focuses on whether trastuzumab-emtansine followed by subcutaneous trastuzumab has fewer side effects than the standard treatment of paclitaxel plus trastuzumab. It also aims to learn about long-term benefits and disease-free survival. Participants will be randomly assigned to one of two treatment groups. One group receives intravenous trastuzumab-emtansine every 3 weeks for 18 weeks, followed by subcutaneous trastuzumab every 3 weeks for 33 weeks. The other group receives weekly intravenous paclitaxel for 12 weeks along with subcutaneous trastuzumab every 3 weeks for 51 weeks the first four doses of trastuzumab are given with paclitaxel. Treatments are given over a total of one year. During the study, participants will undergo screening, laboratory tests, and follow-up visits. Researchers will monitor side effects and measure disease-free survival for up to 72 months after randomization. Quality of life, symptoms, work productivity, cardiac function, and gene profiling will also be evaluated. Participants will be followed for five years after completing treatment to collect long-term data.

Age: 18Years +All GendersPhase 2
53 locations
P

Actively Recruiting

Researchers are evaluating the use of carboplatin chemotherapy given before surgery in patients with high-risk prostate cancer who have inherited mutations in the BRCA1 or BRCA2 genes. This phase II trial aims to determine how well carboplatin works in shrinking tumors prior to surgery and to assess its impact on disease progression and survival. The study also monitors treatment side effects and collects tissue samples for future research. Participants receive carboplatin intravenously before undergoing prostate surgery. Those who show signs of disease progression after surgery will have imaging tests such as CT, MRI, chest X-ray, or PSMA PET scans. Blood samples are collected throughout the trial to monitor health and support additional studies. The study includes detailed follow-up to evaluate treatment outcomes and safety. During the trial, participants will have regular assessments including physical exams, PSA tests, and imaging scans if needed. Researchers will review the rate of complete tumor response after carboplatin treatment at surgery and track progression-free survival and overall survival over time. Safety and side effects of the treatment are closely monitored. Participation may last up to five years with ongoing collection of health data and specimens.

Age: 18Years +MALEPhase 2
133 locations

1-10 of 55

1